Obesity Abstracts

SGLT2 inhibitors (SGLT2Is) are increasingly prescribed for patients with Type 2 Diabetes (T2D) as they are associated with cardiovascular benefit and weight loss with low risk of hypoglycaemia. However, in the last few years, euglycemic ketoacidosis has emerged as a recognized complication of treatment with SGLT2I. The challenge lies in delayed recognition and treatment as it can be easily overlooked due to the conspicuous absence of marked hyperglycaemia. Ketoacidosis can als...